Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B17 | O75795 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10286052 | 0.95 | UGT2B17 (0.41) | UGT2B17ACHEDRD2DRD1 | |
| SCHEMBL10286132 | 0.83 | CHRM4 (0.38) | NPC1RAB9ADRD2KDM4EALDH1A1 | |
| SCHEMBL10286146 | 0.81 | GRM1 (0.37) | UGT2B17NPC1RAB9AKDM4E | |
| SCHEMBL10286195 | 0.81 | UGT2B17 (0.30) | UGT2B17 | |
| SCHEMBL10286093 | 0.80 | UGT2B17 (0.34) | UGT2B17ACHE | |
| SCHEMBL10286124 | 0.79 | KDM4E (0.36) | ACHENPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL10286129 | 0.79 | NPY5R (0.32) | — | |
| SCHEMBL10286048 | 0.79 | ACHE (0.38) | UGT2B17ACHEKDM4EALDH1A1 | |
| SCHEMBL10286372 | 0.79 | UGT2B17 (0.36) | UGT2B17ACHE | |
| SCHEMBL10286292 | 0.79 | UGT2B17 (0.36) | UGT2B17ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012001040-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | MSR1, DDT, MPO | UGT2B17 1446/4885ACHE 660/4885NPC1 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.